Accelerate your journey with viral vector-basted cell therapies and the enhancements you can incorporate. Building a solid foundation and getting support in your journey from critical raw materials to commercial supply through a flexible and transparent partnership can be key in your scalable success.
Navigating the complexities of the rapidly evolving landscape of cell therapy manufacturing poses significant challenges. This emphasizes the need for closed, automated, and flexible manufacturing workflows that are designed to de-risk the process for clinical and commercial success. Join this webinar to learn more about the challenges facing cell therapy developers by Dark Horse’s Anne Lamontagne and how Catalent has responded by developing the UpTempo℠ CAR-T Platform process, a workflow based on our experience of supporting 20+ cell therapy programs with 500+ manufactured batches. Catalent’s Rupa Pike will explain the key characteristics of the platform which include:
Offered Free by: Catalent
See All Resources from: Catalent